Protection and selection for gene therapy in the hematopoietic system.
AffiliationCancer Research UK Gene Therapy Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractHematopoietic stem cell gene therapy is potentially curative for a number of inherited and acquired disorders. However, poor gene transfer and expression in repopulating hematopoietic stem cells attenuate this potential. Here we review potential means of conferring a selective advantage to hematopoietic stem cells and their progeny, and discuss the issues that surround the use of selective advantages in vivo.
CitationProtection and selection for gene therapy in the hematopoietic system. 2004, 6 (2):133-46 J Gene Med
JournalThe Journal of Gene Medicine
- Reduction in hematopoietic stem cell numbers with in vivo drug selection can be partially abrogated by HOXB4 gene expression.
- Authors: Sawai N, Persons DA, Zhou S, Lu T, Sorrentino BP
- Issue date: 2003 Sep
- Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
- Authors: Trobridge GD, Beard BC, Wu RA, Ironside C, Malik P, Kiem HP
- Issue date: 2012
- Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene.
- Authors: Chung J, Scherer LJ, Gu A, Gardner AM, Torres-Coronado M, Epps EW, Digiusto DL, Rossi JJ
- Issue date: 2014 May
- Sleeping Beauty-Mediated Drug Resistance Gene Transfer in Human Hematopoietic Progenitor Cells.
- Authors: Hyland KA, Olson ER, McIvor RS
- Issue date: 2015 Oct
- Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.
- Authors: Milsom MD, Williams DA
- Issue date: 2007 Aug 1